Basiliximab

Red

Brand Name(s):Simulect

Indication:Renal transplantation (immunosuppressive therapy)

Rationale:1,2,8

Considered:Jun-09

Review Date:Jan-25

Comments:
MHRA Drug safety information: information at http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con465930.pdf
Sept 2014
…………………………
Basiliximab or daclizumab, used as part of calcineurin-inhibitor-based
immunosuppression, are considered as options for induction therapy in
the prophylaxis of acute organ rejection in adults undergoing renal
transplantation. The induction therapy with the lowest acquisition cost
is used, unless it is contraindicated.

NICE TA 85
September 2004
Immunosuppressive therapy for renal transplantation in adults

Immunosuppressive therapy for renal transplantation in children and adolescents NICE TA99 guidance can be found at: http://publications.nice.org.uk/immunosuppressive-therapy-for-renal-transplantation-in-children-and-adolescents-ta99